Luminex Co. (LMNX) Director Sells $804,902.40 in Stock

Luminex Co. (NASDAQ:LMNX) Director G Walter Loewenbaum II sold 39,456 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $20.40, for a total transaction of $804,902.40. Following the transaction, the director now owns 651,736 shares in the company, valued at $13,295,414.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

G Walter Loewenbaum II also recently made the following trade(s):

  • On Thursday, December 14th, G Walter Loewenbaum II sold 31,739 shares of Luminex stock. The stock was sold at an average price of $20.49, for a total transaction of $650,332.11.
  • On Thursday, November 16th, G Walter Loewenbaum II sold 50,000 shares of Luminex stock. The stock was sold at an average price of $21.79, for a total transaction of $1,089,500.00.

Shares of Luminex Co. (NASDAQ:LMNX) opened at $20.55 on Friday. Luminex Co. has a 52 week low of $17.68 and a 52 week high of $22.42. The company has a market capitalization of $897.39, a price-to-earnings ratio of 35.12, a P/E/G ratio of 2.56 and a beta of 0.19.

Luminex (NASDAQ:LMNX) last announced its quarterly earnings data on Monday, October 30th. The medical instruments supplier reported $0.25 EPS for the quarter, beating the consensus estimate of $0.19 by $0.06. The business had revenue of $74.14 million during the quarter, compared to analyst estimates of $74.38 million. Luminex had a return on equity of 6.01% and a net margin of 9.52%. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.21 earnings per share. analysts predict that Luminex Co. will post 0.49 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 12th. Shareholders of record on Friday, December 22nd will be given a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a yield of 1.17%. The ex-dividend date is Thursday, December 21st. Luminex’s dividend payout ratio is currently 36.36%.

Several research analysts have recently issued reports on LMNX shares. Jefferies Group restated a “hold” rating and issued a $21.00 target price on shares of Luminex in a report on Friday, October 20th. BidaskClub cut shares of Luminex from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th. Zacks Investment Research upgraded shares of Luminex from a “hold” rating to a “strong-buy” rating and set a $22.00 target price on the stock in a report on Thursday, August 24th. TheStreet upgraded shares of Luminex from a “c+” rating to a “b-” rating in a report on Wednesday, November 1st. Finally, ValuEngine upgraded shares of Luminex from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $20.00.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its position in Luminex by 14.1% during the second quarter. BlackRock Inc. now owns 5,776,500 shares of the medical instruments supplier’s stock valued at $121,999,000 after buying an additional 713,436 shares during the period. Vanguard Group Inc. raised its position in shares of Luminex by 1.0% in the 2nd quarter. Vanguard Group Inc. now owns 3,479,055 shares of the medical instruments supplier’s stock worth $73,477,000 after purchasing an additional 32,995 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Luminex by 15.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,841,540 shares of the medical instruments supplier’s stock worth $38,893,000 after purchasing an additional 252,299 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Luminex by 3.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,819,417 shares of the medical instruments supplier’s stock worth $36,989,000 after purchasing an additional 61,437 shares during the last quarter. Finally, State Street Corp raised its position in shares of Luminex by 6.1% in the 2nd quarter. State Street Corp now owns 1,071,007 shares of the medical instruments supplier’s stock worth $22,620,000 after purchasing an additional 61,218 shares during the last quarter. 79.19% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/16/luminex-co-lmnx-director-sells-804902-40-in-stock.html.

Luminex Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Insider Buying and Selling by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply